Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
19
DTIL Quote, Financials, Valuation and Earnings
Last price:
$4.52
Seasonality move
:
-21.67%
Day range:
$4.45 - $4.65
52-week range:
$4.13 - $19.43
Dividend yield:
0%
P/E ratio:
75.00x
P/S ratio:
0.35x
P/B ratio:
0.53x
Volume:
63.8K
Avg. volume:
130.2K
1-year change:
-59.48%
Market cap:
$34.5M
Revenue:
$48.7M
EPS (TTM):
$0.06
Analysts' Opinion
-
Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.60, Precision BioSciences has an estimated upside of 646.67% from its current price of $4.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $4.50.
Fair Value
-
According to the consensus of 4 analysts, Precision BioSciences has 646.67% upside to fair value with a price target of $33.60 per share.
DTIL vs. S&P 500
-
Over the past 5 trading days, Precision BioSciences has underperformed the S&P 500 by -4.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Precision BioSciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Precision BioSciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Precision BioSciences reported revenues of $576K.
Earnings Growth
-
Precision BioSciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Precision BioSciences reported earnings per share of -$2.25.
Enterprise value:
-44.4M
EV / Invested capital:
-0.51x
Price / LTM sales:
0.35x
EV / EBIT:
-3.30x
EV / Revenue:
-0.59x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-2.36x
Gross Profit (TTM):
--
Return On Assets:
5.21%
Net Income Margin (TTM):
11.48%
Return On Equity:
19.19%
Return On Invested Capital:
12.8%
Operating Margin:
-3693.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $20.8M | $52.3M | $75.1M | $13.1M | $576K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$102.3M | -$41M | -$16.2M | -$12.4M | -$21.3M | |
| EBITDA | -$87.3M | -$37.4M | $18.8M | -$9.5M | -$15.2M | |
| Diluted EPS | -$45.60 | -$19.78 | $0.06 | -$2.10 | -$2.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $122.6M | $183M | $225.4M | $145.9M | $110.5M | |
| Total Assets | $168.7M | $227.2M | $271.7M | $164.3M | $153.3M | |
| Current Liabilities | $42M | $36.5M | $61.1M | $50.6M | $12M | |
| Total Liabilities | $104.9M | $125.8M | $187.4M | $135.3M | $88.4M | |
| Total Equity | $63.8M | $101.4M | $84.4M | $29.1M | $64.9M | |
| Total Debt | -- | $2.5M | $22.2M | $22.4M | $22.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$47.6M | -$97.5M | -$48.2M | -$23.1M | -$5.9M | |
| Cash From Investing | -$4.2M | $5.2M | -$76K | $7.6M | -$64K | |
| Cash From Financing | $103.4M | $2.6M | $47.4M | -$34K | $3.7M | |
| Free Cash Flow | -$51.8M | -$100.4M | -$48.4M | -$23.5M | -$6M | |
DTIL
Sector
Market Cap
$34.5M
$46.1M
Price % of 52-Week High
23.16%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-70.3%
-0.6%
1-Year Price Total Return
-59.48%
-30.52%
Beta (5-Year)
1.408
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.66
200-day SMA
Sell
Level
$9.82
Bollinger Bands (100)
Sell
Level
6.71 - 9.91
Chaikin Money Flow
Sell
Level
-78.7M
20-day SMA
Sell
Level
$5.66
Relative Strength Index (RSI14)
Sell
Level
30.71
ADX Line
Buy
Level
23.11
Williams %R
Buy
Level
-83.0353
50-day SMA
Sell
Level
$7.17
MACD (12, 26)
Sell
Level
-0.81
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-2.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.9746)
Sell
CA Score
(Annual)
Level (-2.6633)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.5804)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Stock Forecast FAQ
In the current month, DTIL has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DTIL average analyst price target in the past 3 months is $33.60.
-
Where Will Precision BioSciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Precision BioSciences share price will rise to $33.60 per share over the next 12 months.
-
What Do Analysts Say About Precision BioSciences?
Analysts are divided on their view about Precision BioSciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Precision BioSciences is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Precision BioSciences's Price Target?
The price target for Precision BioSciences over the next 1-year time period is forecast to be $33.60 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DTIL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Precision BioSciences is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DTIL?
You can purchase shares of Precision BioSciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Precision BioSciences shares.
-
What Is The Precision BioSciences Share Price Today?
Precision BioSciences was last trading at $4.52 per share. This represents the most recent stock quote for Precision BioSciences. Yesterday, Precision BioSciences closed at $4.50 per share.
-
How To Buy Precision BioSciences Stock Online?
In order to purchase Precision BioSciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
